Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

MORU's new Critical Care Asia Network: 42 ICUs in 9 countries

MORU Bangkok

In partnership with the Wellcome Innovations Flagship Programme, MORU launched its Critical Care Asia Network project with its first investigators’ meeting on 19-20 Aug in Bangkok. The project will establish an Asian ICU network across 42 ICUs in nine countries and implement a setting-adapted electronic registry.

Group photo of Critical care workshop attendees

Using the registry as well as qualitative methods, this project will evaluate the quality of critical care within the network, which will then lead into locally-led quality improvement interventions aiming to improve ICU performance and patient outcomes.

Building on methodology developed by our partners in Sri Lanka, Pakistan and India, the electronic registry will provide epidemiological data and map processes of care, involving caregivers and patients and family members. This will be complemented by qualitative evaluations of care processes, with the aim to empower healthcare teams to identify targets for improvement. Quality improvement interventions and research will be driven by priorities set by the network collaborators. The project works in close collaboration with the Flagship project lead by the OUCRU team on developing new low-cost technologies for ICUs in low/middle income countries. The network will also provide a platform for clinical trials planned for the next phase of the project. Follow the project on Twitter, as well via Rashan’s Twitter handle.

Above photo, collaborators at the Bangkok meeting (front row, from left): Dr Khamsay Detleuxay, Dr Nguyen Thien Binh, Dr Lakshmi Rangananthan, Dr Sophie Yacoub, Dr Rebecca Inglis, Dr Gyan Kayastha, Dr Mavuto Mukaka, Dr Victoria Adewole, Dr Louise Thwaites; (middle row): Dr Nguyen Thanh Nguyen , Dr Dong Phu Khiem, Dilanthi Gamage, Dr Lam Minh Yen, Dr Kathleen Thomas, Dr Bui Thi Hanh Duyen,  Dr Duong Bich Thuy, Dr Madiha Hashmi, Prof Ramani Moonesinghe, Dr Rozina Sultana, Abi Beane, Dr Syed Muhammad Muneeb Ali; (back row): Dr Arshad Taqi, Dr Dinh Minh Duc, Dr Rashan Haniffa, Dr Will Schilling, Ishara Udayanga, Prof. Marcus Schultz, Dr Swagata Tripathy, Prof Arjen M. Dondorp, Dr Muhammad Hayat, Dr Diptesh Aryal. Absent: Dr Steve Harris, Dr Bharath Kumar, Dr Jorge Salluh, Dr Meghan Lever, Dr Chris Pell, Dr Tamilarasu Kadhiravan, Dr Chairat Permpikul, Dr Ratapum Champunot, Dr Gentle Shrestha, Dr Rajyabardhan Pattnaik, Prof Guy Thwaites and Prof Yoell Lubell.

­- With thanks to Abi Beane for text and Jan Ariyalikit for photos

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.

COPCOV investigators meet, and prepare to submit for publication

On 15-16 Dec, COPCOV investigators from around the world met in Bangkok to review study results and plan next steps. Led by co-PIs Prof Sir Nick White and Dr Will Schilling, and funded by the Wellcome Trust, the MORU-led COPCOV ( Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting) is the world’s largest multinational trial of COVID-19 prevention.